Our second product candidate, ALLN-346, is designed to be a first-in-class, orally-administered non-absorbed urate-degrading enzyme. We have developed ALLN-346 to degrade urate in the GI tract and in turn, reduce the urate burden on the kidney and lower the risk of urate related complications, including gouty flares and arthritis and urate-based stones in the kidney, bladder, and/or urinary tract. We are initially targeting ALLN-346 for patients with hyperuricemia and moderate to severe CKD.